Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deborah Ainsworth

Pediatrics Washington, NC Medical Doctor

NPI 1578675955 CMS profile 207949

1206 Brown St, Washington, NC 27889

Open in the dashboard

General payments

$1,199

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deborah Ainsworth of Washington, NC is reported in the CMS Open Payments database as having received $1,199 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $101 5
2024 General $219 11
2023 General $199 10
2022 General $364 20
2021 General $125 8
2020 General $34 2
2019 General $157 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Ainsworth
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Deborah Ainsworth were reported at $101. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Deborah Ainsworth Pediatrics median Middle half National median
2019 $157 $86 $31–$183 $163
2020 $34 $49 $22–$110 $114
2021 $125 $68 $27–$158 $132
2022 $364 $77 $30–$173 $149
2023 $199 $88 $33–$190 $160
2024 $219 $94 $34–$206 $164
2025 $101 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $373 22 payments
  2. Corium, Inc. $173 8 payments
  3. Ironshore Pharmaceuticals Inc. $156 8 payments
  4. Merck Sharp & Dohme Corporation $106 7 payments
  5. Tris Pharma Inc $91 5 payments
  6. Sanofi Pasteur Inc. $72 4 payments
  7. GlaxoSmithKline, LLC. $58 3 payments
  8. Pfizer Inc. $44 3 payments
  9. Sanofi-Aventis U.S. LLC $28 1 payment
  10. Mirum Pharmaceuticals, Inc. $24 1 payment
  11. Other $75 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,199 66 payments
Products named General payments · program years 2019–2025
  1. QELBREE $373 22 payments
  2. Azstarys $173 8 payments
  3. VAXNEUVANCE $94 6 payments
  4. VAXELIS $78 5 payments
  5. JORNAY PM Central Nervous System Stimulant $67 3 payments
  6. GARDASIL 9 $63 4 payments
  7. JORNAY PM Central Nervous Stimulant ADHD $58 3 payments
  8. BEXSERO $58 3 payments
  9. Quillivant XR $54 3 payments
  10. TRUMENBA $44 3 payments
  11. Other $537 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$38,653

Of which drugs: $29,341

Medicare patients

236

Average age 76

Services billed

636

134 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 42%
Diabetes 26%
Ischemic heart disease 24%
Osteoporosis 17%
Atrial fibrillation 14%
Chronic kidney disease 14%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 138 138 $18,934
Vaccine for influenza for injection into muscle 90662 Office 159 159 $9,952

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $67
$67 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $46
$46 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $28
$28 — —
Livmarli
  • Mirum Pharmaceuticals, Inc. $24
$24 — —
Dyanavel XR
  • Tris Pharma Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record